Suzetrigine in the Management of Pain Review of the First-in-class Na V1.8 Selective Inhibitor
Abstract
Introduction. The 2025 FDA approval of suzetrigine (Journavx) ended a 25-year stagnation in analgesic development. This introduced a paradigm shift in pain management. As a first-in-class, highly selective NaV1.8 sodium channel inhibitor, suzetrigine addresses the urgent need for potent, non-opioid options for moderate-to-severe acute pain. It targets channels that are expressed almost exclusively in peripheral nociceptors. Thus, it decouples robust analgesia from systemic risks and addictive potential inherent to traditional opioid therapies.
Aim of the study. This review evaluates the status of suzetrigine as of 2026, focusing on its molecular mechanism, clinical efficacy, and safety data from pivotal Phase 3 trials, as well as its broader impact on public health and healthcare economics.
Materials and methods. A systematic literature review was conducted using PubMed (up to early 2026). Analysis included structural molecular studies, Phase 2/3 clinical trials (NAVIGATE-1 and -2), and budget impact models regarding the opioid crisis.
Conclusions. Suzetrigine represents a significant breakthrough in pain medicine, boasting a 31,000-fold selectivity for NaV1.8, thereby safeguarding the cardiac and central nervous systems. Clinical data demonstrate efficacy comparable to opioid pain therapy, but without respiratory depression, sedation, or physical dependence. Non-opioid mechanisms create measurable, substantial savings by preventing opioid-related adverse events and…
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.